Results 231 to 240 of about 53,118 (291)

Inhibition of ErbB2 mitigates secondary denervation after traumatic muscle injury

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Our study evaluated the therapeutic potential of ErbB2 inhibition (Herceptin) after volumetric muscle loss (VML) injury, primarily evaluating improvements at the neuromuscular junctions (NMJ). A full thickness model of VML injury to the tibialis anterior muscle of adult Lewis rats was used, and treatments included Herceptin, a ...
Jacob R. Sorensen   +6 more
wiley   +1 more source

Germ cell and other tumors in individuals with differences in sex development

open access: yesCA: A Cancer Journal for Clinicians, EarlyView.
Abstract Approximately one in 3500 to one in 5100 live‐born infants have atypical external genital development, known as differences in sex development (DSD). In 2005, an expert consensus conference thoroughly reviewed aspects of health care for individuals with DSD.
Selma Feldman Witchel   +1 more
wiley   +1 more source

Human sporadic breast carcinoma histotypes driven by the Human Betaretrovirus homologous to Mouse Mammary Tumor Virus

open access: yesInternational Journal of Cancer, Volume 157, Issue 2, Page 371-383, 15 July 2025.
What's new? While estrogens, obesity, and alcohol are recognized risk factors for breast cancer, a viral hypothesis has been suggested based on the murine model of Mouse Mammary Tumor Virus (MMTV)‐induced mammary tumors. This study analyzed sequences of the human homolog of MMTV across human breast carcinoma histotypes, detecting the virus in all types
Prospero Civita   +12 more
wiley   +1 more source

Liver‐Directed Gene Therapy Mitigates Early Nephropathy in Murine Glycogen Storage Disease Type Ia

open access: yesJournal of Inherited Metabolic Disease, Volume 48, Issue 4, July 2025.
ABSTRACT Nephropathy is a complication of glycogen storage disease type Ia (GSD‐Ia), a metabolic disorder caused by pathogenic variants in glucose‐6‐phosphatase‐α (G6Pase‐α or G6PC1). While maintaining blood glucose homeostasis can delay the progression of renal disease in GSD‐Ia, the benefits of liver‐directed G6PC1 gene therapy on nephropathy remain ...
Cheol Lee   +7 more
wiley   +1 more source

High‐throughput screening identifies bazedoxifene as a potential therapeutic for dysferlin‐deficient limb girdle muscular dystrophy

open access: yesBritish Journal of Pharmacology, Volume 182, Issue 13, Page 2930-2949, July 2025.
Abstract Background and Purpose Limb‐girdle muscular dystrophy R2 (LGMD R2) is a rare genetic disorder characterised by progressive weakness and wasting of proximal muscles. LGMD R2 is caused by the loss of function of dysferlin, a transmembrane protein crucial for plasma membrane repair in skeletal muscles.
Celine Bruge   +10 more
wiley   +1 more source

Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double‐blind trial

open access: yesDiabetes, Obesity and Metabolism, Volume 27, Issue 7, Page 3943-3956, July 2025.
Abstract Background Sodium‐glucose cotransporter (SGLT) 2 inhibitors attenuate fasting glomerular hyperfiltration in people with type 2 diabetes (T2D). However, SGLT2‐inhibition increases glucagon levels, which facilitate postprandial hyperfiltration.
Michaël J. B. van Baar   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy